Stifel Financial’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Stifel Financial’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-29,067	Closed	-$122K	–	3469
2023 Q1	$122K	Buy	29,067 +200	+0.7%	+$1.04K	﹤0.01%	3148
2022 Q4	$173K	Buy	28,867 +2,500	+9%	+$13.6K	﹤0.01%	3015
2022 Q3	$153K	Hold	26,367	–	–	﹤0.01%	3019
2022 Q2	$157K	Hold	26,367	–	–	﹤0.01%	3075
2022 Q1	$123K	Buy	+26,367	New	+$78.6K	﹤0.01%	3232

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Stifel Financial's CTIC Position: Q2 2023 in Review

Stifel Financial sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 29,067 shares — an estimated $122K sold.

Stifel Financial first reported a position in CTIC in Q1 2022 and held it in 5 quarters. The position peaked at $173K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Stifel Financial reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Stifel Financial sold 29,067 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $122K.
Stifel Financial first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 5 quarters.
Stifel Financial's CTI BioPharma Corp. (DE) Common Stock position peaked at $173K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Stifel Financial's 13F filing for Q2 2023, filed 14 Aug 2023.